Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Advances in HematologyOpen Access

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKevin H. LinLHLynn HuynhXYXiaoqin Yang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows treatment discontinuation impacts progression-free survival in CLL patients, highlighting urgent need for new strategies.

Key Points

  • Median progression-free survival from BTKi initiation was 3.2 years, pointing to the need for better treatment options as patient outcomes vary significantly.
  • Patients discontinuing BTKi showed a notable correlation between progression-free survival and overall survival (r = 0.79), indicating the complexity of treatment response.
  • Over half of patients received BCL2i after BTKi, but 73.8% eventually discontinued, raising concerns about long-term efficacy of current regimens.
  • High rates of progressive disease (15.0%) were observed in relapsed or refractory patients, emphasizing the need for new therapeutic strategies in this population.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/693231368e51979591dceadehttps://doi.org/10.1155/ah/7492594
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  2. 2Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China2025
  3. 3Real-world discontinuation of cBTKi-based treatments in patients with CLL/SLL in the United States2025
  4. 4Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025
  5. 5Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025